NKT Immune Cell Therapy is a treatment that can treat parental cancer cells using immune cells of blood-related children, which means more advanced technology than conventional NK cell therapy.

NKT cell therapy research status

Recent animal experiments in Japan have shown that using natural killer cells (iPS) technology has successfully proven that natural killer T cells in humans are effective against cancer. We are conducting animal experiments to demonstrate the effects of human leukocyte antigens (HLA), and we have secured safety through advanced clinical trials. 

What is NKT Immune Cell Therapy?

NKT cells are natural killer T cells, which are T and B lymphocytes, different from NK cells, with a specific marker of one of the immune cells. NKT cell surface shows specific markers on the surface of NK cells such as CD3, TCRαβ, and NK1.1 CD16, CD56, and others. In general, when NKT cells are activated, they resist the infection of various microorganisms and activate other immune cells through cell factor secretion and so on. 

As shown in the figure, NKT cells with strong anticancer effects are activated in vitro and then injected back into the body. This treatment is Japan's advanced medical technology to maximize the effect for preventing post-surgical metastasis in Japan. The advantage of this technique is that any patient can be treated for any cancer. The possible reason for this is the activation of natural immune cells, so the side effects are relatively small. The left picture is DC dendritic cell activated after proliferation in vitro, and the right figure is NKT cell activated in vitro. All are injected into the body to activate NKT cells in the body while supplementing NKT cells and acting as anticancer agents. 

Phase 2 clinical data of patients with advanced lung cancer

Observations with outpatient treatment of 17 patients with advanced lung cancer (> 10 NKT / ml) revealed no increase, metastasis, or recurrence of the tumor, even with initial treatment alone and no subsequent treatment.